JP2009501745A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009501745A5 JP2009501745A5 JP2008521869A JP2008521869A JP2009501745A5 JP 2009501745 A5 JP2009501745 A5 JP 2009501745A5 JP 2008521869 A JP2008521869 A JP 2008521869A JP 2008521869 A JP2008521869 A JP 2008521869A JP 2009501745 A5 JP2009501745 A5 JP 2009501745A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- substituted
- compound according
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 125000003545 alkoxy group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- LAQGPQNMQRFDIM-UHFFFAOYSA-N 4-(2,4-difluorobenzoyl)-1-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]piperazin-2-one Chemical compound CC1CCCN1CCCOC1=CC=C(N2C(CN(CC2)C(=O)C=2C(=CC(F)=CC=2)F)=O)C=C1 LAQGPQNMQRFDIM-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000938 histamine H1 antagonist Substances 0.000 claims 1
- 239000004335 litholrubine BK Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0514812.7A GB0514812D0 (en) | 2005-07-19 | 2005-07-19 | Compounds |
| PCT/EP2006/007036 WO2007009741A1 (en) | 2005-07-19 | 2006-07-17 | Piperazinone derivatives useful as histamine h3 receptor antagonists and/or inverse agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009501745A JP2009501745A (ja) | 2009-01-22 |
| JP2009501745A5 true JP2009501745A5 (cg-RX-API-DMAC10.html) | 2009-09-10 |
Family
ID=34897470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008521869A Pending JP2009501745A (ja) | 2005-07-19 | 2006-07-17 | ヒスタミンｈ３受容体アンタゴニストおよび／または逆アゴニストとして有用なピペラジノン誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080275027A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1906964A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2009501745A (cg-RX-API-DMAC10.html) |
| GB (1) | GB0514812D0 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2007009741A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0514811D0 (en) * | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| KR20100017565A (ko) | 2007-05-03 | 2010-02-16 | 세파론, 인코포레이티드 | (ｒ)-2-메틸피롤리딘 및 (ｓ)-2-메틸피롤리딘 및 이의 타르트레이트 염의 제조 방법 |
| WO2009063953A1 (ja) * | 2007-11-13 | 2009-05-22 | Taisho Pharmaceutical Co., Ltd. | フェニルピラゾール誘導体 |
| WO2009067406A1 (en) * | 2007-11-20 | 2009-05-28 | Janssen Pharmaceutica N.V. | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
| EP2222664B1 (en) | 2007-11-20 | 2014-10-29 | Janssen Pharmaceutica, N.V. | Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor |
| EP2285803A4 (en) | 2008-05-23 | 2011-10-05 | Amira Pharmaceuticals Inc | Inhibitor of 5-Lipoxygenase Activating Protein |
| JP5740838B2 (ja) * | 2009-05-12 | 2015-07-01 | 大正製薬株式会社 | フェニルピラゾール誘導体 |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| PE20170185A1 (es) | 2014-05-12 | 2017-04-01 | Glaxosmithkline Intellectual Property (No 2) Ltd | Composiciones farmaceuticas para tratar enfermedades infecciosas |
| EP3183248B1 (en) | 2014-08-21 | 2020-11-11 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
| WO2017034990A1 (en) | 2015-08-21 | 2017-03-02 | Portola Pharmaceuticals, Inc. | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity |
| WO2017034994A1 (en) | 2015-08-21 | 2017-03-02 | Portola Pharmaceuticals, Inc. | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity |
| WO2017034997A1 (en) * | 2015-08-21 | 2017-03-02 | Portola Pharmaceuticals, Inc. | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (pcsk9) modulators and their use |
| US20190119236A1 (en) | 2016-02-23 | 2019-04-25 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| CN108486155A (zh) * | 2018-04-27 | 2018-09-04 | 中国医学科学院输血研究所 | 构建Doxycycline/Mifepristone诱导过表达的带有荧光蛋白标记基因的双诱导表达载体 |
| CA3173172A1 (en) | 2020-03-26 | 2021-09-30 | Christopher D. Kane | Cathepsin inhibitors for preventing or treating viral infections |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60130460T2 (de) * | 2000-07-13 | 2008-06-05 | Abbott Laboratories, Abbott Park | 1,3-disubstituierte und 1,3,3-trisubstituierte pyrrolidine als liganden des histamin-3 rezeptors und ihre therapeutischen anwendungen |
| GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| AU2003274053A1 (en) * | 2002-10-22 | 2004-05-13 | Glaxo Group Limited | Aryloxyalkylamine derivates as h3 receptor ligands |
| GB0308333D0 (en) * | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
-
2005
- 2005-07-19 GB GBGB0514812.7A patent/GB0514812D0/en not_active Ceased
-
2006
- 2006-07-17 JP JP2008521869A patent/JP2009501745A/ja active Pending
- 2006-07-17 EP EP06762670A patent/EP1906964A1/en not_active Withdrawn
- 2006-07-17 WO PCT/EP2006/007036 patent/WO2007009741A1/en not_active Ceased
- 2006-07-17 US US11/995,929 patent/US20080275027A1/en not_active Abandoned